Mahajan, 70 patient remdesivir late treatment RCT: 76% higher mortality [p=0.47] and 112% higher ventilation [p=0.42] https://c19p.org/mahajan
copied to clipboard
Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study
et al., Indian Journal of Anasthesia, doi:10.4103/ija.IJA_149_21
Small RCT with 34 remdesivir patients and 36 controls finding no significant difference in clinical outcomes.[Gérard, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
|
risk of death, 76.5% higher, RR 1.76, p = 0.47, treatment 5 of 34 (14.7%), control 3 of 36 (8.3%).
|
|
risk of mechanical ventilation, 111.8% higher, RR 2.12, p = 0.42, treatment 4 of 34 (11.8%), control 2 of 36 (5.6%).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Mahajan et al., 3/20/2021, Randomized Controlled Trial, India, South Asia, peer-reviewed, 3 authors, average treatment delay 6.84 days.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.